Potential therapeutic effects of naringin loaded PLGA nanoparticles for the management of Alzheimer's disease: In vitro, ex vivo and in vivo investigation

Dashputre, Neelam L.; Laddha, Umesh D.; Darekar, Prajakta P.; Kadam, Jayesh D.; Patil, Surbhi B.; Sable, Rahul R.; Udavant, Pavan B.; Tajanpure, Anjali B.; Kakad, Smita P.; Kshirsagar, Sanjay J.

doi:10.1016/j.heliyon.2023.e19374

Cited by 4 publications

(1 citation statement)

References 22 publications

(56 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Appropriate quantities of GRb1, GRb1@PLGA@NPs, and PLGA@NPs samples were individually freeze-dried, and the resulting freeze-dried powders were deposited onto glass slides. Testing was conducted using a Bruker D8 Advance X-ray diffractometer with a diffraction scanning angle of 2θ, scanning within the range of 5 ~ 90° 22 , while observing the diffraction peaks of the samples.…”

Section: Methodsmentioning

confidence: 99%

Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles

Du,

Lu,

Xiao

et al. 2023

Sci Rep

View full text Add to dashboard Cite

This study aimed to construct a Ginsenoside Rb1-PLGA nano drug delivery system, optimize its preparation process, characterize and evaluate the resulting Ginsenoside Rb1-PLGA Nanoparticles (GRb1@PLGA@NPs). GRb1@PLGA@NPs were prepared using the emulsion solvent evaporation method. The optimal preparation process was determined using Plackett–Burman design combined with Box-Behnken experiments. Physical characterization and in vitro release studies were conducted. LC–MS/MS technique was employed to investigate the pharmacokinetic characteristics of GRb1 and GRb1@PLGA@NPs in rat plasma. The optimal preparation process yielded GRb1@PLGA@NPs with a particle size of 120.63 nm, polydispersity index (PDI) of 0.172, zeta potential of − 22.67 mV, encapsulation efficiency of 75%, and drug loading of 11%. In vitro release demonstrated sustained drug release. Compared to GRb1, GRb1@PLGA@NPs exhibited a shortened time to peak concentration by approximately 0.72-fold. The area under the plasma concentration–time curve significantly increased to 4.58-fold of GRb1. GRb1@PLGA@NPs formulated using the optimal process exhibited uniform distribution and stable quality, its relative oral bioavailability was significantly improved compared to free GRb1.

show abstract

Section: Methodsmentioning

confidence: 99%

Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles

Du,

Lu,

Xiao

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

Naringin: A flavanone with a multifaceted target against sepsis-associated organ injuries

Bajgai,

Suri,

Singh

et al. 2024

Phytomedicine

View full text Add to dashboard Cite

Development Optimization of Sorafenib-Loaded Plga Nanoparticles Guided by in Silico Computational Tools

PARIDA,

PATTNAIK,

BEHERA

et al. 2024

Int J App Pharm

View full text Add to dashboard Cite

Objective: The purpose of this study was to develop, characterize, and optimize sorafenib-loaded Poly (lactic-co-glycolic acid) PLGA polymeric nanoparticles for prolonged delivery of sorafenib for improved hepatic cancer treatment Methods: The drug-excipient interaction was explored by molecular docking studies within silico tools. The drug-loaded polymeric nanoparticles were prepared by single emulsion solvent evaporation method using box-bhenkan design and characterized for particle size, zeta potential, and entrapment efficiency. Shape and surface morphology was analysed by Transmission Electron Microscopy (TEM). In vitro drug release study was performed by using a diffusion membrane. Results: The docking analysis inferred that the drug has interacted well with PLGA and PF-68, which could prevent the drug crystal formation. The optimized polymeric nanoparticles had a particle size of 175 nm, Entrapment Efficiency (EE) of 85.1% and zeta potential of-23.8mV were found to be within 95% of CI of the predicted value, which is acceptable. TEM studies showed that the formed polymeric nanoparticles were smooth, spherical in shape and uniform in size. In vitro drug release study of optimized formulation showed extended release for sorafenib. Conclusion: Based on the computational studies and in vitro release studies, the developed Sorafenib loaded in PLGA nanoparticles could be a promising formulation in oral drug delivery for the treatment of liver cancer.

show abstract

Potential therapeutic effects of naringin loaded PLGA nanoparticles for the management of Alzheimer's disease: In vitro, ex vivo and in vivo investigation

Cited by 4 publications

References 22 publications

Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles

Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles

Naringin: A flavanone with a multifaceted target against sepsis-associated organ injuries

Development Optimization of Sorafenib-Loaded Plga Nanoparticles Guided by in Silico Computational Tools

Contact Info

Product

Resources

About